Latest Period
Q1 2026
Security Snapshot
Arcus Biosciences, Inc. - Common Stock (RCUS) Institutional Ownership
CUSIP: 03969F109
13F Institutional Holders and Ownership History from Q1 2018 to Q1 2026
Institutions Reporting
204
Shares (Excl. Options)
118,326,035
Price
$21.60
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- RCUS on NYSE
- Shares outstanding
- 122,470,452
- Price per share
- $24.52
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 118,326,035
- Total reported value
- $2,556,108,890
- % of total 13F portfolios
- 0%
- Share change
- -2,800,777
- Value change
- -$72,334,834
- Number of holders
- 204
- Price from insider filings
- $24.52
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- RCUS - Arcus Biosciences, Inc. - Common Stock is tracked under CUSIP 03969F109.
- 204 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 206 to 204 between Q4 2025 and Q1 2026.
- Reported value moved from $2,893,303,857 to $2,556,108,890.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 204 institutions filings for Q1 2026.
Investment Quick Answers
What is CUSIP 03969F109?
CUSIP 03969F109 identifies RCUS - Arcus Biosciences, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q1 2026 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 03969F109:
Significant Owners of Arcus Biosciences, Inc. - Common Stock (RCUS) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 26% | -14% | $427,376,736 | 31,424,760 | 0% | GILEAD SCIENCES, INC. | 03 Nov 2025 | |
| BlackRock, Inc. | 10% | +11% | $303,514,602 | +$65,766,227 | 12,736,927 | +28% | BlackRock, Inc. | 31 Dec 2025 |
| Point72 Asset Management, L.P. | 4.1% | -28% | $58,921,714 | -$20,381,232 | 4,332,479 | -26% | Point72 Asset Management, L.P. | 30 Sep 2025 |
As of 31 Mar 2026, 204 institutional investors reported holding 118,326,035 shares of Arcus Biosciences, Inc. - Common Stock (RCUS). This represents 97% of the company’s total 122,470,452 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Arcus Biosciences, Inc. - Common Stock (RCUS) together control 83% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 26% | 31,424,760 | 0% | 32% | $678,774,816 |
| BlackRock, Inc. | 12% | 15,226,475 | +1.5% | 0.01% | $328,891,861 |
| WELLINGTON MANAGEMENT GROUP LLP | 5% | 6,089,516 | +17% | 0.02% | $131,533,546 |
| STATE STREET CORP | 4.4% | 5,412,901 | +18% | 0% | $116,918,662 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 4.1% | 5,030,993 | -3% | 2.9% | $108,669,449 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.5% | 4,272,056 | 0% | 0% | $92,276,410 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.1% | 3,856,725 | 0% | 0% | $83,305,260 |
| Woodline Partners LP | 3.1% | 3,777,798 | +0.21% | 0.31% | $81,600,437 |
| MARSHALL WACE, LLP | 3.1% | 3,761,437 | +11% | 0.09% | $81,247,040 |
| Siren, L.L.C. | 2.5% | 3,007,077 | 0% | 1.8% | $64,952,863 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.8% | 2,252,367 | +18% | 0% | $48,659,380 |
| Fisher Asset Management, LLC | 1.8% | 2,190,404 | +12% | 0.02% | $47,312,724 |
| SAMLYN CAPITAL, LLC | 1.6% | 1,908,412 | +19% | 0.71% | $41,221,700 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1.4% | 1,654,754 | -1.9% | 0.04% | $35,742,686 |
| DIMENSIONAL FUND ADVISORS LP | 1.2% | 1,426,223 | -6.4% | 0.01% | $30,801,780 |
| CITADEL ADVISORS LLC | 1.1% | 1,329,935 | +1170% | 0.02% | $28,726,596 |
| Parkman Healthcare Partners LLC | 0.99% | 1,207,274 | +25% | 2.7% | $26,077,118 |
| Logos Global Management LP | 0.98% | 1,200,000 | 1.3% | $25,920,000 | |
| FMR LLC | 0.95% | 1,165,252 | +2.6% | 0% | $25,169,435 |
| MORGAN STANLEY | 0.91% | 1,113,526 | -8% | 0% | $24,052,175 |
| Trails Edge Capital Partners, LP | 0.86% | 1,047,935 | +14% | 5.3% | $22,635,396 |
| GOLDMAN SACHS GROUP INC | 0.82% | 999,786 | -14% | 0% | $21,595,378 |
| Sofinnova Investments, Inc. | 0.75% | 923,086 | -16% | 1% | $19,938,658 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.74% | 903,638 | -6.7% | 0% | $19,518,581 |
| NORTHERN TRUST CORP | 0.69% | 840,305 | +5.7% | 0% | $18,150,587 |
Institutional Holders of Arcus Biosciences, Inc. - Common Stock (RCUS) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 118,326,035 | $2,556,108,890 | -$72,334,834 | $21.60 | 204 |
| 2025 Q4 | 121,424,270 | $2,893,303,857 | +$498,497,157 | $23.83 | 206 |
| 2025 Q3 | 100,610,243 | $1,368,169,306 | +$17,470,409 | $13.60 | 186 |
| 2025 Q2 | 99,735,332 | $811,386,525 | +$23,005,595 | $8.14 | 181 |
| 2025 Q1 | 97,195,653 | $762,981,433 | +$76,941,552 | $7.85 | 183 |
| 2024 Q4 | 83,908,968 | $1,249,338,646 | -$21,214,675 | $14.89 | 185 |
| 2024 Q3 | 53,324,923 | $815,463,718 | +$21,618,657 | $15.29 | 184 |
| 2024 Q2 | 51,955,193 | $791,285,512 | -$15,709,425 | $15.23 | 191 |
| 2024 Q1 | 52,828,671 | $997,275,069 | +$741,376 | $18.88 | 169 |
| 2023 Q4 | 52,818,611 | $1,008,878,346 | -$1,266,933 | $19.10 | 181 |
| 2023 Q3 | 52,811,112 | $947,947,087 | -$30,726,648 | $17.95 | 184 |
| 2023 Q2 | 54,702,646 | $1,110,123,478 | -$11,409,103 | $20.31 | 177 |
| 2023 Q1 | 55,490,875 | $1,012,137,432 | +$17,396,401 | $18.24 | 177 |
| 2022 Q4 | 53,808,832 | $1,112,728,096 | +$17,661,819 | $20.68 | 199 |
| 2022 Q3 | 52,505,739 | $1,373,608,654 | -$54,087 | $26.16 | 171 |
| 2022 Q2 | 52,444,913 | $1,329,092,467 | -$15,970,235 | $25.34 | 162 |
| 2022 Q1 | 50,609,470 | $1,598,261,880 | -$43,817,366 | $31.56 | 146 |
| 2021 Q4 | 50,826,972 | $2,056,609,533 | +$107,109,155 | $40.47 | 136 |
| 2021 Q3 | 48,251,727 | $1,682,950,642 | +$59,932,851 | $34.87 | 127 |
| 2021 Q2 | 45,147,112 | $1,239,729,813 | +$11,589,356 | $27.46 | 125 |
| 2021 Q1 | 44,736,322 | $1,254,917,338 | +$7,899,154 | $28.08 | 143 |
| 2020 Q4 | 44,575,673 | $1,157,187,273 | +$10,417,742 | $25.96 | 143 |
| 2020 Q3 | 44,391,126 | $760,991,949 | +$17,571,170 | $17.14 | 127 |
| 2020 Q2 | 41,840,912 | $1,034,233,021 | +$380,488,277 | $24.74 | 138 |
| 2020 Q1 | 26,992,583 | $374,653,368 | -$448,171 | $13.88 | 92 |
| 2019 Q4 | 23,560,774 | $237,962,351 | -$3,030,738 | $10.10 | 74 |
| 2019 Q3 | 25,809,690 | $234,896,496 | -$672,043 | $9.10 | 73 |
| 2019 Q2 | 26,440,928 | $210,047,107 | +$6,023,856 | $7.95 | 76 |
| 2019 Q1 | 25,799,127 | $322,227,437 | -$12,715,178 | $12.49 | 63 |
| 2018 Q4 | 26,918,679 | $289,911,060 | -$4,742,182 | $10.77 | 66 |
| 2018 Q3 | 22,437,315 | $312,774,356 | +$950,561 | $13.94 | 56 |
| 2018 Q2 | 22,392,855 | $274,091,081 | +$31,576,470 | $12.24 | 61 |
| 2018 Q1 | 16,255,471 | $250,516,107 | +$250,516,106 | $15.44 | 55 |